Artificial intelligence in drug development for delirium and Alzheimer's disease.
10.1016/j.apsb.2025.04.026
- Author:
Ruixue AI
1
;
Xianglu XIAO
2
;
Shenglong DENG
2
;
Nan YANG
2
;
Xiaodan XING
2
;
Leiv Otto WATNE
3
;
Geir SELBÆK
4
;
Yehani WEDATILAKE
4
;
Chenglong XIE
5
;
David C RUBINSZTEIN
6
;
Jennifer E PALMER
6
;
Bjørn Erik NEERLAND
7
;
Hongming CHEN
8
;
Zhangming NIU
9
;
Guang YANG
2
;
Evandro Fei FANG
1
Author Information
1. Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Lørenskog 1478, Norway.
2. Bioengineering Department and Imperial-X, Imperial College London, London W12 7SL, UK.
3. Department of Geriatric Medicine, Akershus University Hospital, Lørenskog 1478, Norway.
4. Norwegian National Centre for Ageing and Health, Vestfold Hospital Trust, Tønsberg 3103, Norway.
5. Department of Neurology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
6. Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge CB2 0XY, UK.
7. Department of Geriatric Medicine, Oslo University Hospital, Oslo 0450, Norway.
8. Guangzhou National Laboratory, Guangzhou 510005, China.
9. Mindrank AI Ltd., Hangzhou 310018, China.
- Publication Type:Review
- Keywords:
Alzheimer’s disease;
Artificial intelligence;
Deep learning;
Delirium;
Drug discovery;
Neurodegeneration;
Target identification
- From:
Acta Pharmaceutica Sinica B
2025;15(9):4386-4410
- CountryChina
- Language:English
-
Abstract:
Delirium is a common cause and complication of hospitalization in the elderly and is associated with higher risk of future dementia and progression of existing dementia, of which 70% is Alzheimer's disease (AD). AD and delirium, which are known to be aggravated by one another, represent significant societal challenges, especially in light of the absence of effective treatments. The intricate biological mechanisms have led to numerous clinical trial setbacks and likely contribute to the limited efficacy of existing therapeutics. Artificial intelligence (AI) presents a promising avenue for overcoming these hurdles by deploying algorithms to uncover hidden patterns across diverse data types. This review explores the pivotal role of AI in revolutionizing drug discovery for AD and delirium from target identification to the development of small molecule and protein-based therapies. Recent advances in deep learning, particularly in accurate protein structure prediction, are facilitating novel approaches to drug design and expediting the discovery pipeline for biological and small molecule therapeutics. This review concludes with an appraisal of current achievements and limitations, and touches on prospects for the use of AI in advancing drug discovery in AD and delirium, emphasizing its transformative potential in addressing these two and possibly other neurodegenerative conditions.
